SK바이오팜

326030KOSPI자연과학 및 공학 연구개발업

55.0 / 100

Reference Date: 2026-04-13

Financial Score23.5 / 40

News Sentiment13.5 / 25

Momentum6.0 / 20

Disclosure12.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but PBR raises overvaluation concerns. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

SK Bios制药 was established in 1993, focusing on innovative drug development for epilepsy and successfully expanding its technology exports to multiple countries, including the U.S. and Europe. Its flagship products, Xenobamate and Solriamfetol, are sold in global markets, with sales reaching 70.67 billion KRW in 2025. The company is also advancing into new therapeutic modalities such as RPT and TPD to expand into oncology.

Number of Employees

272people

Average Salary

109.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

28.89Industry Average 120.078.0Point

Half of industry avg (excellent)

PBR

9.34Industry Average 3.820.0Point

2.4x industry avg (risky)

ROE

36.17Industry Average -32.113.5Point

Well below industry avg

Debt Ratio

9.30Industry Average 7.522.0Point

Higher than industry avg (caution)

Trend 2023~202510.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲41.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲234.2% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 25.3% (improving, 3yr)

Detailed News Sentiment

46 totalPositive 5Neutral 35Negative 1Average Sentiment Score 54.6

Detailed Momentum

52-week position1.0Point

Near 52w low (19%, downtrend)

Current 98,500Won52-week high 140,70052-week low 88,500

1-month return3.0Point

1m 0.72% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 1Neutral 7Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-04-01
Neutral주식등의대량보유상황보고서(일반)2026-03-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-31
Neutral최대주주등소유주식변동신고서2026-03-31
Neutral정기주주총회결과2026-03-26